Skip Navigation LinksHome > March 2008 - Volume 15 - Issue 2 > Pulmonary Complications of Novel Antineoplastic Agents for H...
Clinical Pulmonary Medicine:
doi: 10.1097/CPM.0b013e3181671a2d
Interstitial, Inflammatory, and Occupational Lung Disease

Pulmonary Complications of Novel Antineoplastic Agents for Hematologic Malignancies

Vahid, Bobbak MD; Marik, Paul E. MD, FCCP

Collapse Box


Pulmonary complications in patients with hematologic malignancies is commonly encountered by clinicians. Some of these complications are believed to be related to direct toxicity of the drug itself. Novel antineoplastic agents with activity against hematologic malignancies are constantly being introduced into practice and clinical trials. This article reviews the pulmonary complications of these novel antineoplastic agents. Interstitial pneumonitis, eosinophilic pneumonia, noncardiogenic pulmonary edema, acute respiratory distress syndrome, pleural disease, and thromboembolic disease associated with individual antineoplastic agents are discussed. Clinical presentations, radiographic findings, pathology, pathogenesis, and management are also reviewed.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.